^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    olanzapine

    i
    Other names: LY-170052, LY 170053
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    DRD2 antagonist, DRD1 antagonist, Serotonin 2A receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    3d
    Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Chinese University of Hong Kong
    New P2 trial
    |
    olanzapine • ondansetron
    5d
    Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (clinicaltrials.gov)
    P3, N=222, Recruiting, Affiliated Hospital of Qinghai University | Initiation date: Sep 2025 --> Feb 2026
    Trial initiation date
    |
    olanzapine
    7d
    A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron (clinicaltrials.gov)
    P=N/A, N=238, Not yet recruiting, Henan Cancer Hospital
    New trial
    |
    dexamethasone • olanzapine
    12d
    An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (clinicaltrials.gov)
    P4, N=5, Terminated, Ohio State University | N=60 --> 5 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; Not able to recruit enough subjects
    Enrollment change • Trial completion date • Trial termination
    |
    olanzapine
    20d
    Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen (clinicaltrials.gov)
    P3, N=92, Recruiting, The Affiliated People's Hospital of Ningbo University
    New P3 trial
    |
    dexamethasone • fosaprepitant • olanzapine
    22d
    The TNF-α-FABP4-Dhhc7 Axis Mediates Olanzapine-Induced Insulin Resistance in Rats and Humans. (PubMed, Clin Exp Pharmacol Physiol)
    In summary, our study demonstrated that long-term exposure to olanzapine increases circulating plasma levels of TNF-α, thus leading to increased expression of FABP4 protein in white adipose tissue and subsequently inhibiting Dhhc7expression, which correspondingly leads to reduced membrane translocation of GLUT4 and consequent insulin resistance. In conclusion, this study elucidated the signalling pathway through which olanzapine inhibits GLUT4 membrane transport via the TNF-α/FABP4/Dhhc7 axis, thus ultimately leading to insulin resistance.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FABP4 (Fatty Acid Binding Protein 4) • SLC2A4 (Solute Carrier Family 2 Member 4)
    |
    olanzapine
    26d
    Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, Shandong Cancer Hospital and Institute
    New trial
    |
    olanzapine
    27d
    Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (clinicaltrials.gov)
    P3, N=360, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    megestrol • olanzapine
    28d
    Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial (clinicaltrials.gov)
    P2, N=66, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    olanzapine
    1m
    Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients (clinicaltrials.gov)
    P3, N=40, Recruiting, Tanta University | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Jun 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    olanzapine
    1m
    Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Central Institute of Mental Health, Mannheim | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    olanzapine
    1m
    Clinical study of the ability of celecoxib combined with olanzapine and paroxetine hydrochloride to improve depression,anxiety and analgesic effects in patients after hemorrhoidal surgery (ChiCTR2500112052)
    P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University
    New trial
    |
    celecoxib oral • olanzapine